Pharmacy retailers can help bring diabetic limb amputations down through education, MTM
WHAT IT MEANS AND WHY IT’S IMPORTANT — Lower-limb amputation is a very real risk for many of the 25.8 million Americans living with diabetes. Though this study may be encouraging, the job of reducing the incidence of diabetes — and in particular, educating people about the need to watch their diets, take their medications and take care of their bodies — remains far from complete, as other recent stories in the media have revealed.
(THE NEWS: CDC study reports drop in lower-limb amputations among diabetes patients. For the full story, click here)
A 10,149-patient Finnish study published earlier this month in the journal Diabetes Care found that many patients at risk of developing Type 2 diabetes don’t see the need to seek lifestyle counseling to prevent themselves from getting the disease and that those who attended a supervised lifestyle intervention were more likely to perceive a need for it than those who agreed to a self-initiated lifestyle change. Meanwhile, celebrity chef Paula Deen attracted widespread criticism for what many saw as hypocrisy after announcing that she would become a paid spokeswoman for a diabetes drug after hiding her Type 2 diabetes for three years, during which she continued eating sugar- and fat-laden foods.
What this all shows is that diabetes and its often tragic consequences remain unknown or at least ignored by a large number of people. Luckily, however, pharmacy retailers are in a position to ensure that patients take their drugs and have the information they need.
With medication therapy management programs, pharmacists can counsel patients to ensure that they take their drugs in the way that their doctors have ordered. Meanwhile, pharmacy retailers — particularly supermarkets and mass merchandisers with big food sections, but also drug stores — can emphasize the importance of maintaining a healthy diet.
Rite Aid, for example, teamed up with celebrity chef Sam Talbot, a Type 1 diabetic and author of the cookbook "The Sweet Life: Diabetes Without Boundaries," to launch the Rite Track Diabetes Tour. CVS has made headway with the Pharmacy Advisor program, which mixes retail and PBM services, and Walgreens has won recognition for its MTM programs. Many supermarkets conduct store tours for people with diabetes. And all three retail formats are in a position to educate diabetes patients about the importance of things like foot care.
Reducing the incidence of diabetes, especially Type 2 — and consequences of the disease, such as amputations and blindness — is going to take a long time, but in pharmacy retailers, the country already has a well-developed infrastructure for providing the most important tool of all: education.
Dollar General CEO joins Lowe’s board
MOORESVILLE, N.C. — Lowe’s has announced the appointment of Rick Dreiling to its board of directors. He will serve on the board’s audit and governance committees. The announcement brings Lowe’s board of directors to 12 members, 11 of whom are independent.
Dreiling is chairman and CEO of Dollar General, a position he has held since 2008. He led Dollar General’s re-emergence as a public company in 2009 through a successful initial public offering on the New York Stock Exchange. Dreiling has extensive retail experience, having served as chairman and CEO of Duane Reade; EVP and COO of Longs Drug Stores; EVP marketing, manufacturing and distribution for Safeway; and president of Vons, a food and drug division of Safeway in Southern California.
“Rick has a tremendous range of retail and executive management experience from his years of working with some of the nation’s top retail companies,” said Robert Niblock, Lowe’s chairman, president and CEO. “He is a thoughtful leader who will be an outstanding complement to Lowe’s board of directors.”
AmerisourceBergen reports $20.4 billion in Q1 revenue
VALLEY FORGE, Pa. — AmerisourceBergen on Thursday reported $20.4 billion in revenue for the first quarter ended Dec. 31, up 2%.
“We are off to a good start in our fiscal year 2012, with December quarter results in line with our expectations and excellent progress being made on the integration of our recent acquisitions,” stated Steven Collis, AmerisourceBergen president and CEO. “We continued to demonstrate expense and working capital discipline, and our balance sheet remains strong, giving us outstanding financial flexibility.”
According to the company, the results were driven by a 3.9% increase in AmerisourceBergen Specialty Group revenue and a 2.1% increase in AmerisourceBergen Drug Corporation revenue. Strong performance in third-party logistics in ABSG and in the retail and institutional segments in ABDC was offset in part by a previously announced loss of a large retail customer. Recent acquisitions, particularly the addition of TheraCom, contributed 0.6% of revenue growth in the quarter.
“Looking ahead, the company continues to expect diluted earnings per share in fiscal year 2012 to be in the range of $2.74 to $2.84,” Collis said. “Also unchanged are the assumptions supporting the expected diluted earnings per share range for fiscal year 2012, including flat to modest revenue growth, operating margin growth in the high single-digit to low double-digit basis points range and free cash flow in the range of $700 million to $800 million, which includes capital expenditures in the $150 million range. Subject to market conditions, we expect to spend approximately $400 million to repurchase our common shares in fiscal year 2012.”